{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:49:02Z","timestamp":1787755742481,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Case:<\/jats:title>\n                    <jats:p>Burosumab is a novel drug developed to treat hereditary fibroblast growth factor 23 (FGF23)-related disorders. We report the case of an 11-year-old girl with McCune-Albright syndrome (MAS) who sustained hypophosphatemia due to excess FGF23 and multiple bone lesions of fibrous dysplasia (FD). Burosumab therapy markedly improved not only the biochemical parameters but also the radiographic appearance of the FD lesions and clinical symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This is the first report to demonstrate that burosumab is effective in improving FD lesions in a patient with MAS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2106\/jbjs.cc.24.00279","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T14:09:04Z","timestamp":1726841344000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Improvement of Fibrous Dysplasia After Burosumab Therapy in a Pediatric Patient with McCune-Albright Syndrome"],"prefix":"10.2106","volume":"14","author":[{"given":"Kenta","family":"Sawamura","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Aichi Children's Health and Medical Center, Obu, Aichi, Japan"},{"name":"Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hamajima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Aichi Children's Health and Medical Center, Obu, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-1586","authenticated-orcid":false,"given":"Hiroshi","family":"Kitoh","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Aichi Children's Health and Medical Center, Obu, Aichi, Japan"},{"name":"Department of Comprehensive Pediatric Medicine, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7]]},"reference":[{"issue":"2","key":"bib1-20240920","doi-asserted-by":"crossref","first-page":"101844","DOI":"10.1016\/j.beem.2023.101844","article-title":"Inherited fibroblast growth factor 23 excess","volume":"38","author":"Cherian","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"1","key":"bib2-20240920","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"bib3-20240920","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous dysplasia\/McCune-Albright Syndrome: a rare, mosaic disease of G\u03b1 s activation","volume":"41","author":"Boyce","year":"2020","journal-title":"Endocr Rev."},{"issue":"2","key":"bib4-20240920","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jbmr.4463","article-title":"Long bone fractures in fibrous dysplasia\/McCune-Albright Syndrome: prevalence, natural history, and risk factors","volume":"37","author":"Geels","year":"2022","journal-title":"J Bone Miner Res."},{"issue":"2","key":"bib5-20240920","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11914-013-0144-5","article-title":"Fibrous dysplasia and fibroblast growth factor-23 regulation","volume":"11","author":"Boyce","year":"2013","journal-title":"Curr Osteoporos Rep."},{"issue":"9","key":"bib6-20240920","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/jbmr.4641","article-title":"Bone matrix mineralization and response to burosumab in adult patients with X-Linked hypophosphatemia: results from the phase 3, single-arm international trial","volume":"37","author":"Fratzl-Zelman","year":"2022","journal-title":"J Bone Miner Res."},{"key":"bib7-20240920","doi-asserted-by":"crossref","first-page":"116004","DOI":"10.1016\/j.bone.2021.116004","article-title":"Burosumab treatment for fibrous dysplasia","volume":"150","author":"Gladding","year":"2021","journal-title":"Bone."},{"issue":"3","key":"bib8-20240920","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000527129","article-title":"Burosumab therapy in a paediatric patient with McCune-Albright syndrome: a case report","volume":"96","author":"Apperley","year":"2023","journal-title":"Horm Res Paediatr."},{"key":"bib9-20240920","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet."},{"key":"bib10-20240920","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"key":"bib11-20240920","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/BPB.0000000000001054","article-title":"Changes of the lower limb deformity in children with FGF23-related hypophosphatemic rickets treated with burosumab: a single-center prospective study","volume":"33","author":"Sawamura","year":"2024","journal-title":"J Pediatr Orthop B."},{"key":"bib12-20240920","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"5","key":"bib13-20240920","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1210\/clinem\/dgad671","article-title":"Serum phosphorus as a driver of skeletal morbidity in fibrous dysplasia","volume":"109","author":"Gun","year":"2024","journal-title":"J Clin Endocrinol Metab."},{"key":"bib14-20240920","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1210\/clinem\/dgad744","article-title":"Incidence and prevalence of fibrous dysplasia\/McCune-Albright syndrome\u2014a nationwide registry-based study in Denmark","volume":"109","author":"Meier","year":"2024","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"bib15-20240920","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s11154-023-09832-2","article-title":"Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis","volume":"24","author":"Bertin","year":"2023","journal-title":"Rev Endocr Metab Disord."},{"issue":"2","key":"bib16-20240920","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jbmr.2999","article-title":"Outcome of long-term bisphosphonate therapy in McCune-Albright syndrome and polyostotic fibrous dysplasia","volume":"32","author":"Majoor","year":"2017","journal-title":"J Bone Miner Res."},{"issue":"12","key":"bib17-20240920","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates","volume":"104","author":"Majoor","year":"2019","journal-title":"J Clin Endocrinol Metab."}],"container-title":["JBJS Case Connector"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.CC.24.00279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:48:04Z","timestamp":1787752084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.CC.24.00279"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.cc.24.00279","relation":{},"ISSN":["2160-3251"],"issn-type":[{"value":"2160-3251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}